Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
akcea therapeutics
alnylam pharmaceuticals
barry greene
biotech & health
boston
boston blog main
boston top stories
boston university
clinical trials
dan ollendorf
drugs
fda
hereditary transthyretin amyloidosis
inotersen
john berk
life sciences
mary o'donnell
national blog main
national top stories
new york blog main
new york top stories
patisiran
regeneron pharmaceuticals
rna interference
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
startups
stem cells
tafamidis
the amyloidosis foundation
the institute for clinical and economic review
vc fund
vyndaqel
What
medicine
3
×
time
3
×
accelerating
ago
alderley
alleviate
alnylam
amadeus
approve
area
awaits
based
bio
biological
biotech
bounds
capital
catapult
cells
centre
cheshire
chief
clearly
commercial
conditions
controversial
controversy
cost
crossed
decades
decision
discovered
discovery
fda
fingers
friday
futuristic
generating
grown
hailed
Language
unset
Current search:
medicine
×
time
×
biotech
×
@techcrunch.com
2 months ago
This Swedish startup wants to reduce the cost, and controversy, around stem cells production
@tech.eu
1 year ago
Amadeus Capital Partners’ Volker Hirsch joins Medicines Discovery Catapult as Chief Commercial Officer
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision